Document is current
Any future updates will be listed below
-
Authors
Kinjo, Megumi https://orcid.org/0009-0003-5392-5349
Tamura, Shunsuke
Sugiyama, Shunsuke
van Weert, Eimi https://orcid.org/0009-0006-4920-8437
Oribe, Naoya
Tsuchimoto, Rikako
Mitoma, Ryo https://orcid.org/0009-0000-1701-356X
Takai, Yoshifumi
Honda, Shiori
Nakajima, Shinichiro https://orcid.org/0000-0002-2601-2195
Hirano, Yoji https://orcid.org/0000-0001-6847-9677
Uhlhaas, Peter J. https://orcid.org/0000-0002-0892-2224
Noda, Yoshihiro https://orcid.org/0000-0002-2155-0357
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (20dk0307093h0001)
Japan Agency for Medical Research and Development (21dk0307093h0002)
Japan Agency for Medical Research and Development (JP24wm0625302)
MEXT | Japan Society for the Promotion of Science (21H02813)
MEXT | Japan Society for the Promotion of Science (20KK0193)
MEXT | Japan Society for the Promotion of Science (21H02851)
- License Information
-
More Information
Article History
Received: 16 February 2025
Revised: 10 December 2025
Accepted: 25 January 2026
First Online: 3 February 2026
Competing interest
: SN has received grants from Japan Society for the Promotion of Science (22H03002, 23K24263, 24K02541, 24K02387, 24K10740, 25K21813, 25K10856, 25K10823), Japan Agency for Medical Research and Development (AMED: JP24wm0625302, JP24wm0625307, 24dk0307104h0003, 22dk0307105h0001), Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Watanabe Foundation, Osakeno-Kagaku Foundation, and Astellas Foundation within the past three years. SN has also received research support, manuscript fees, or speaker’s honoraria from Asahi Quality & Innovations, Ltd., Teijin Pharma, Sumitomo Pharma, Meiji Seika Pharma, Otsuka, PDR pharma, and MSD within the past three years. YN has received investigator-initiated clinical study grants from Teijin Pharma Ltd. and Inter-Reha Co., Ltd. He received a research grant from the Watanabe Foundation and the Daiichi Sankyo Scholarship Donation Program. He has received speaker honoraria from Sumitomo Pharma Co., Ltd., Teijin Pharma Ltd., Takeda Pharmaceutical Co., Ltd., Lundbeck Japan Co., Ltd., Viatris Inc., and Otsuka Pharmaceutical Co., Ltd. within the past 3 years, outside the submitted work. He received equipment-in-kind support for an investigator-initiated study from Magventure, Inc., Inter-Reha Co., Ltd., and Miyuki Giken Co., Ltd.
: As this study is a meta-analysis of previously published literature and does not involve the use of any individual-level identifiable data, ethics approval and consent to participate were not required. All procedures were conducted in accordance with the PRISMA guideline.
